ReviewCells2022
Clinical Trials Using Mesenchymal Stem Cells for Spinal Cord Injury: Challenges in Generating Evidence.
Review in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- The neuroprotective and therapeutic potential of resveratrol for traumatic spinal cord injuries: a systematic review.BMC neurology · 2026Pooled it
- Mesenchymal Stromal/Stem Cells in Chronic Incomplete Traumatic Spinal Cord Injury: A Phase I/II Double-Blind Placebo-Controlled Multicentre Trial.Biomedicines · 2026Article
- Developing an NT3-loaded exosomal biodegradable conductive hydrogel combined with EA for targeted treatment of spinal cord injury.Materials today. Bio · 2025Article
- Ultrasound-driven wireless piezoelectric hydrogel synergizes with cotransplantation of NSCs-hUCMSCs for structural and functional recovery in spinal cord injury.Materials today. Bio · 2025Article
- Review
- Personalized Stem Cell-Based Regeneration in Spinal Cord Injury Care.International journal of molecular sciences · 2025Review
- Intranasal Delivery of Brain-Derived Neurotrophic Factor (BDNF)-Loaded Small Extracellular Vesicles for Treating Acute Spinal Cord Injury in Rats and Monkeys.Journal of extracellular vesicles · 2025Article
- Adverse events of cell therapy clinical trials in human chronic spinal cord injury, a systematic review and meta-analysis.Regenerative therapy · 2024Review
- Mesenchymal stromal cell therapies for traumatic neurological injuries.Journal of translational medicine · 2024Review
- Medical Ozone as a Therapeutic Option in Musculoskeletal Pain Control: A Critical Review of Clinical Trials Considering Safety and Quality Indicators for Procedures and Devices.The Yale journal of biology and medicine · 2024Review
- Stem cell therapies for neurological disorders: current progress, challenges, and future perspectives.European journal of medical research · 2024Review
- Pericyte derivation and transplantation for blood-CNS barrier reconstitution in CNS disorders.IBRO neuroscience reports · 2024Article
- Transplantation of autologous mesenchymal stromal cells in complete cervical spinal cord injury: a pilot study.Frontiers in medicine · 2024Article
- Autophagy regulation combined with stem cell therapy for treatment of spinal cord injury.Neural regeneration research · 2023Review
- Circulating exosomal lncRNA contributes to the pathogenesis of spinal cord injury in rats.Neural regeneration research · 2023Article
- Molecular Mechanisms and Clinical Application of Multipotent Stem Cells for Spinal Cord Injury.Cells · 2022Review
- Therapeutic Strategy of Mesenchymal-Stem-Cell-Derived Extracellular Vesicles as Regenerative Medicine.International journal of molecular sciences · 2022Review
- Application and prospects of somatic cell reprogramming technology for spinal cord injury treatment.Frontiers in cellular neuroscience · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 2 countries.
Funding
Abstract
Spinal cord injury (SCI) remains an important public health problem which often causes permanent loss of muscle strength, sensation, and function below the site of the injury, generating physical, psychological, and social impacts throughout the lives of the affected individuals, since there are no effective treatments available. The use of stem cells has been investigated as a therapeutic approach for the treatment of SCI. Although a significant number of studies have been conducted in pre-clinical and clinical settings, so far there is no established cell therapy for the treatment of SCI. One aspect that makes it difficult to evaluate the efficacy is the heterogeneity of experimental designs in the clinical trials that have been published. Cell transplantation methods vary widely among the trials, and there are still no standardized protocols or recommendations for the therapeutic use of stem cells in SCI. Among the different cell types, mesenchymal stem/stromal cells (MSCs) are the most frequently tested in clinical trials for SCI treatment. This study reviews the clinical applications of MSCs for SCI, focusing on the critical analysis of 17 clinical trials published thus far, with emphasis on their design and quality. Moreover, it highlights the need for more evidence-based studies designed as randomized controlled trials and potential challenges to be addressed in context of stem cell therapies for SCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.